Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis
about
Therapeutic Drug Monitoring of Posaconazole: an UpdateTranslational Research for Tuberculosis Elimination: Priorities, Challenges, and ActionsA new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Challenges in the clinical assessment of novel tuberculosis drugs.Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.Selected culture and drug-susceptibility testing methods for drug-resistant Mycobacterium tuberculosis screening in resource-constrained settings.An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosisThe role of delamanid in the treatment of drug-resistant tuberculosis.Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.A modest proposal for dropping poor arms in clinical trials.Drug-Resistant Tuberculosis: Challenges and Progress.Planning multi-arm screening studies within the context of a drug development program.High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.In vitro and in vivo studies of a rapid and selective breath test for tuberculosis based upon mycobacterial CO dehydrogenase.New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.Emerging drugs and alternative possibilities in the treatment of tuberculosis.Controlling the family-wise error rate in multi-arm, multi-stage trials.Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.Ethics, error, and initial trials of efficacyInnovative trial designs to improving tuberculosis drug development.The 50th anniversary of the Kefauver-Harris Amendments: efficacy assessment and the randomized clinical trial.Statistical considerations for pediatric multidrug-resistant tuberculosis efficacy trials.World TB Day 2014: Reach the three million: a TB test, treatment and cure for all
P2860
Q26746016-F0250EBA-31A3-42E7-BE7C-571A6CDD8251Q26765051-47F2DA1C-5035-4E47-8CC6-C43904B17DA8Q28602112-4AA5EBDB-16B8-489B-9804-68FBC92187AFQ30251933-DFFDFFBB-DFAC-4B75-A201-0A39DC117316Q30901894-596C9AD2-ABF5-4306-BB3C-1FA2D536F010Q34660618-D4D4C3BA-F188-4B16-891B-49ADCC994315Q34718431-F6B1EA11-896C-45E1-AD40-F71F5C5345C2Q35042658-8F987E46-5987-4507-9B13-1D4B172B7B99Q35624245-7B379FD3-4EDC-4948-8A76-49812994D0E5Q35906959-898E416A-33CC-4850-ABD2-0EB431F04D54Q35915044-BD4DC7B2-D59D-48DD-890D-67BDCE56B48BQ36094215-FEF66846-3BA6-49FB-9AB9-BC2BC203ACCEQ36331009-33A2EEE5-B600-47F6-9ACA-F16D09700F6CQ36924283-F250C1AF-14FE-4501-9A7F-3F0B88594233Q37440391-C8931AFD-9112-42D3-B0ED-064536C66541Q37507802-97B86967-9A7B-4F17-A288-D7A1E463B1C3Q37714067-F585EE08-4CFE-48EE-A743-C72A0CCD14B0Q37996998-498EDFA3-296E-4E99-992B-0FDEFF6AE68FQ38724073-6E21BF9D-894E-41EA-AB21-2B979CF29044Q40198381-13667067-05FE-4ED5-B931-5FA78537EE7BQ41857207-61B1038F-0387-49A9-8993-55AF923BDC92Q42395017-CF2D6AB4-C3EC-420D-9E61-77279ACAF1F5Q42534085-AAE1EF42-777C-4A39-8FBF-48BAB4BADED9Q48360943-2688D55E-52D7-4A2A-BF6F-8C02A12D6262Q53692122-14C2902D-7921-4261-9A83-E754B9AC1C3DQ58484965-8264733E-DED3-4031-B9A6-679778868130
P2860
Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis
description
im März 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 22 March 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2012
@uk
name
Innovative Trial Designs Are P ...... the Treatment of Tuberculosis
@en
Innovative Trial Designs Are P ...... the Treatment of Tuberculosis
@nl
type
label
Innovative Trial Designs Are P ...... the Treatment of Tuberculosis
@en
Innovative Trial Designs Are P ...... the Treatment of Tuberculosis
@nl
prefLabel
Innovative Trial Designs Are P ...... the Treatment of Tuberculosis
@en
Innovative Trial Designs Are P ...... the Treatment of Tuberculosis
@nl
P2093
P50
P356
P1476
Innovative trial designs are p ...... the treatment of tuberculosis
@en
P2093
Charles Mgone
Christian Lienhardt
Martin Boeree
Michael Hoelscher
Michel Pletschette
Richard Hafner
Rob Aarnoutse
Tim McHugh
P304
P356
10.1093/INFDIS/JIS041
P407
P433
P478
205 Suppl 2
P577
2012-03-22T00:00:00Z